Clinical Trial Update: Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a triple therapy of asunaprevir, daclatasvir, and BMS-791325 for hepatitis C genotype 4 after failure of pegylated interferon-ribavir…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• Daclatasvir (daclatasvir)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Hepatitis C Virus Genotype 4 Infection | Phase 2 | Status: WITHDRAWN